Cimetidine has been shown to stimulate prolactin secretion after intravenous administration. Cimetidine 200 mg and ranitidine 50 mg was given i.v. in a randomly allocated order to 22 volunteers on consecutive days; these doses can be regarded as equivalent as far as inhibition of gastric acid output is concerned. Plasma prolactin was estimated at regular intervals. The prolactin stimulating effect of cimetidine was confirmed while ranitidine did not influence plasma prolactin levels.
Introduction
Intravenous administration of cimetidine stimulates prolactin secretion (Burland et al., 1979; Carlson and Ippoliti, 1977) whereas oral cimetidine treatment in conventional doses does not influence the basal or releasing hormone-stimulated values of prolactin, thyroid-stimulating hormone and luteinizing hormone (Nelis and van de Meene, 1980) .
A newly synthesized histamine H2-receptor antagonist ranitidine (Glaxo AH 19065) has recently been entered into controlled clinical trials at the Sophia Ziekenhuis. Peden, Saunders and Wormsley (1979) demonstrated a dose-dependent reduction in nocturnal and pentagastrin-stimulated acid output after intra-duodenal instillation of ranitidine. The reduction in acid output after 80 mg ranitidine was comparable to the effect of 400 mg cimetidine. Domschke, Lux and Domschke (1979) In pre-menopausal women, the phase of the menstrual cycle was determined by history, plasma progesterone and plasma oestradiol. The women were presumed to be in the luteal phase if plasma progesterone exceeded 17 nmol/l and plasma oestradiol exceeded 330 pmol/l. Sera were separated and stored at -20°C. All samples were assayed together. The hormones were estimated by radioimmunoassay using CEA-IRE-SORIN (CIS) kits (Fleurus, Belgium) for prolactin (MRC standard 71/222) and commercial kits from Behringwerke-Hoechst (Frankfurt, Germany) for progesterone and oestradiol. Ranitidine was kindly supplied by the Medical Department of Glaxo Allenburys Research (Ware) Ltd (batch 8 CTR/6853).
The matched Student's t-test for paired observations was used for statistical analysis, each subject serving as his/her own control.
All volunteers gave informed consent and the study was conducted according to the Declaration of Helsinki.
Results Table 1 shows the average plasma prolactin values in response to cimetidine and to ranitidine in the 1  304  298  259  291  271  47  47  46  63  45  II  255  251  247  246  214  26  33  17  27  30  III  362  358  357  346  352  59  55  57  55  50 group as a whole, while the figures for the groups taken separately are given in Table 2 . The plasma prolactin stimulating effect of cimetidine is evident at 15, 30 and 60 min after injection (P< 0-01) while ranitidine does not influence plasma prolactin values at 15, 30, 60 and 90 min after injection (P > 0 05). The differences between the plasma prolactin values after cimetidine and ranitidine are statistically significant at 15, 30 and 60 min (P< 0-01) for the group as a whole. For the sub-groups the difference is statistically significant (P<0-01) at 15, 30 and 60 min in the post-menopausal women but only at 15 and 30 min after injection in pre-menopausal women and males.
Plasma prolactin values on the first day of testing are not different from those on the second day (331-4 ,uu./ml v. 319-8 ,tu./ml) irrespective of whether cimetidine or ranitidine was given on the first day.
Basal values before cimetidine administration were no different from those before ranitidine administration, neither in the group as a whole (304-6 ,uu./ml ± 44 s.e. mean v. 302-0 l±u./ml±36 s.e. mean) nor in the sub-groups taken separately. Table 3 shows the percentage maximal increase in plasma prolactin in relation to the phase of the menstrual cycle in pre-menopausal women; no influence on either cimetidine response nor ranitidine response could be established. (Flind, Rowley-Jones and Backhouse, 1980) . The prolactin-secreting effect of i.v. administered cimetidine is widely proved whereas its mechanism of action is still unclear. Direct action on brain histamine receptors, depletion of hypothalamic dopamine stores and dopamine antagonism at the pituitary receptor site have all been proposed (Arakelian and Libertun, 1977; Burland et al., 1979) .
This study showed that ranitidine in equivalent doses to those of cimetidine as regards reduction of gastric acid output failed to stimulate prolactin secretion, so the effect on gastric acid output does not parallel the effect on prolactin-secretion. This could mean that ranitidine does not penetrate into the pituitary as cimetidine does (Cross, 1977) 
